High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

Nimotuzumab (h-R3) is a humanized monoclonal antibody that is safe to use against epidermal growth factor receptor (EGFR). However, the available information is insufficient about the dose effect of monoclonal antibody against epidermal growth factor receptor for the treatment of esophageal squamous...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Onco Targets Ther
Auteurs principaux: Wang, Chunyu, Fu, Xiaolong, Cai, Xuwei, Wu, Xianghua, Hu, Xichun, Fan, Min, Xiang, Jiaqing, Zhang, Yawei, Chen, Haiquan, Jiang, Guoliang, Zhao, Kuaile
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2015
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4699509/
https://ncbi.nlm.nih.gov/pubmed/26766917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S89592
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires